CMS Keeps “Functional Equivalence” In 2004; Amgen Submits Aranesp Data
Executive Summary
Amgen has submitted data to the Centers for Medicare & Medicaid Services suggesting reimbursement for Aranesp should be increased by more than 50% in the final 2004 Hospital Outpatient Prospective Payment System rule
You may also be interested in...
Faslodex, Aranesp Have Special Status Under Hospital Payment Rule
CMS is proposing to allow separate Medicare payments for Faslodex, Trelstar and argatroban use in the hospital outpatient setting when the products become ineligible for "pass-through" payments in 2005
Faslodex, Aranesp Have Special Status Under Hospital Payment Rule
CMS is proposing to allow separate Medicare payments for Faslodex, Trelstar and argatroban use in the hospital outpatient setting when the products become ineligible for "pass-through" payments in 2005
Procrit, Aranesp Reimbursement Adjusted; CMS Splits The Difference
The new payment formula for J&J's Procrit (epoetin alfa) and Amgen's Aranesp (darbepoetin alfa) under the Medicare Hospital Outpatient Prospective Payment System reflects the ratio of dosing used by Medicare providers in chemotherapy patients, CMS said